ClinicalTrials.gg
RecruitingNCT06511739Updated Jul 22, 2024

A Study to Evaluate the Efficacy and Safety of SYHX1901 Tablet in Non-segmental Vitiligo Patients

A Phase 2 interventional study of SYHX1901 and placebo in Non-segmental Vitiligo, sponsored by CSPC Ouyi Pharmaceutical Co., Ltd.. Recruiting at 1 site in China. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2024-07-22.

Sponsored by CSPC Ouyi Pharmaceutical Co., Ltd. (part of CSPC Pharmaceutical Group Limited) · Phase 2, Interventional, and Treatment

From the registry’s dates

  • Primary completion was expected by Aug 2025, 1 year 3 months ago, but the record still lists the study as recruiting.
  • Started May 2024; still recruiting 2 years 5 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
144
Allocation
Randomized
Ages
18 Years to 65 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 39 studies in Vitiligo with a site in China — 24 open to participants now, 29 under way, 8 of them phase 3. Vitiligo · China.

Planned enrollment
17th of 32
144 · median 150
Started
2024
with 4 others
Phase 2
11 of 39
8 open now
Primary completion
2025-08
later than 1 of 28 live
Registered
14th of 39
by date
Lead sponsor
1 of 39
CSPC Ouyi Pharmaceutical Co., Ltd.

Among the 39 studies in Vitiligo with a site in China, this one is the 17th largest by planned enrollment of the 32 interventional ones that give a count, is one of 5 that started in 2024, is one of 11 in phase 2, reaches primary completion later than 1 of the 28 other live ones, and was the 14th registered.

Vitiligo

343 studies on the registry are indexed under Vitiligo; 96 are open to participants now.

Browse Vitiligo studies →

Open to participants now

24 of the 39 studies in Vitiligo with a site in China are open now. Recruiting first, the newest first:

18 more — sign in →

All 24 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 48 Vitiligo studies recruiting now, 13 (27%) set no upper age limit and 29 (60%) stop at 75 or younger; 18 take children under 18; 8 take healthy volunteers.

This study: 18 Years to 65 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 39 studies in Vitiligo with a site in China, or all of them as a file.
02

Study summary

A 52-Week Study of SYHX1901 tablet in Adults with non-segmental vitiligo.

Read the detailed description

SYHX1901 tablet is being evaluated for the treatment of non-segmental vitiligo. The study will enroll approximately 144 participants aged 18-65 with non-segmental vitiligo in 4 treatment arms. Participants will either receive study drug vs placebo oral tablets once daily (QD) for 24 weeks (Period A). In Period B (up to 52 weeks), participants who received placebo during the first 24 weeks will switch to study drug. Participants who received study drug during the first 24 weeks, will continue to receive study drug.

03

Conditions studied

  • Non-segmental Vitiligo

Browse trials for

04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Willing to sign an ICF, able to comprehend and comply with the study procedures.
  2. Male or female subjects aged 18 to 65,inclusive.
  3. Subjects with a clinical diagnosis of non-segmental vitiligo.
  4. Agree to stop all other treatments for vitiligo during the study period.
  5. Women of must have a negative serum pregnancy test within 3 days prior to the first study agent administration.

Exclusion criteria

Exclusion Criteria:

  1. Diagnosed as other active depigmentation disease.
  2. At screening or baseline visits, subject exhibits active inflammatory dermatologic disease or symptoms that in the opinion of investigators would interfere of vitiligo evaluation or response to treatment.
  3. Uncontrolled thyroid function at screening as determined by the investigator.
  4. Use of permanent depigmentation treatment or skin grafts.
  5. Use of phototherapy, topical or systemic treatments within certain time frame prior to Day1.
  6. Have active bacterial/virus/other pathogens infection or infestation that require medical intervention.
  7. Have progressive or uncontrolled systemic disease, or other concomitant chronic disease that the investigators believe unsuitable to participate the study.
  8. History of alcohol and drug abuse within one year prior to screening; History of neurological or mental disorders with diagnosis records, such as severe depression, suicidal tendencies, epilepsy, dementia, etc.
  9. Have any other reasons determined by the investigator that the subject is not eligible for the study.
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
144 participants (estimated)

Study arms

  • Experimental
    SYHX1901-A

    Participants in this group will receive dose A of SYHX1901 orally once daily (QD) for 52 weeks

    Drug: SYHX1901

  • Experimental
    SYHX1901-B

    Participants in this group will receive dose B of SYHX1901 orally QD for 52 weeks

    Drug: SYHX1901

  • Experimental
    SYHX1901-C

    articipants in this group will receive dose C of SYHX1901 orally QD for 52 weeks

    Drug: SYHX1901

  • Placebo comparator
    Placebo followed by dose C of SYHX1901

    Participants in this group will receive placebo orally QD for 24 weeks followed by dose C of SYHX1901 orally QD for 28 weeks.

    Drug: SYHX1901 · Drug: placebo

Interventions

  • SYHX1901 tablet

  • Drugplacebo

    Oral tablet

06

What researchers measure

Primary outcomes

  1. Percent Change From Baseline in Facial-Vitiligo Area Scoring Index (F-VASI)

    The vitiligo area scoring index (VASI) is a validated scoring method used to assess the areas of depigmentation due to vitiligo. The F-VASI includes contributions from the face, with a possible range from 0 to 3.5.

    Time frame: At 24 weeks

Secondary outcomes

  1. Percentage of Participants Achieving F-VASI 50 (≥ 50% Improvement in F-VASI From Baseline)

    The VASI is a validated scoring method used to assess the areas of depigmentation due to vitiligo. The F-VASI includes contributions from the face, with a possible range from 0 to 3.5.

    Time frame: At 4、8、12、16、20、24、28、32、36、40、44、48、52、56 weeks

  2. Percentage of Participants Achieving F-VASI 75 (≥ 75% Improvement in F-VASI From Baseline)

    The VASI is a validated scoring method used to assess the areas of depigmentation due to vitiligo. The F-VASI includes contributions from the face, with a possible range from 0 to 3.5.

    Time frame: At 4、8、12、16、20、24、28、32、36、40、44、48、52、56 weeks

  3. Percentage of Participants Achieving Total Vitiligo Area Scoring Index (T-VASI) 50 (≥ 50% Improvement in T-VASI From Baseline)

    The VASI is a validated scoring method used to assess the areas of depigmentation due to vitiligo. It is based on a composite estimate of the overall area of vitiligo patches, measured by the number of hand units (palm plus 5 digits = 1% body surface area \[BSA\]) multiplied by the degree of depigmentation within each affected area (0%, 10%, 25%, 50%, 75%, 90%, or 100%). The T-VASI is calculated using a formula that includes contributions from all body regions, with a possible range from 0 to 100.

    Time frame: At 4、8、12、16、20、24、28、32、36、40、44、48、52、56 weeks

  4. Percent Change From Baseline in F-VASI

    The VASI is a validated scoring method used to assess the areas of depigmentation due to vitiligo. The T-VASI is calculated using a formula that includes contributions from all body regions, with a possible range from 0 to 100.

    Time frame: At 4、8、12、16、20、24、28、32、36、40、44、48、52、56 weeks

  5. Percent Change From Baseline in BSA

    The BSA is measured by the number of hand units (palm plus 5 digits = 1% body surface area).

    Time frame: At 4、8、12、16、20、24、28、32、36、40、44、48、52、56 weeks

  6. Change from baseline in Overall Dermatology Life Quality Index (DLQI) score

    The DLQI is a validated questionnaire used in dermatology clinical trials as patient reported outcome measure. The DLQI consists of 10 questions concerning patients' perception of the impact of skin diseases on different aspects of their health-related quality of life over the last week.

    Time frame: At 8、16、24、32、40、48、52、56 weeks

  7. Change from baseline in Hospital Anxiety and Depression Scale (HADS) score

    The HADS is a self-rating patient reported outcome measure (PROM) to assess depression and anxiety in patients. Fourteen items are equally divided in two subscales: anxiety (HADS-A) and depression (HADS-D).

    Time frame: At 8、16、24、32、40、48、52、56 weeks

07

Study locations

1 of 1 sites recruiting
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started May 2024 (actual). Primary completion is estimated for Aug 2025, 14 months after the start.

Of 44 phase 2 interventional studies under Vitiligo, half reached primary completion within 19 months of starting (the median), counting those still running; a quarter within 16 and three quarters within 26. This study's planned 14 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 2, 2024
First posted
Jul 22, 2024
StartActual
May 27, 2024
Primary completionEst.
Aug 1, 2025
CompletionEst.
Oct 1, 2025
Last update
Jul 22, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 22, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT06511739
Collaborators
Zhongqi Pharmaceutical Technology (Shijiazhuang) Co. Ltd.
Responsible party
Sponsor
First posted
Jul 22, 2024
Start date
May 27, 2024
Primary completion
Aug 1, 2025 (estimated)
Completion
Oct 1, 2025 (estimated)
Last update
Jul 22, 2024

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

No contact was published for this record. The registry link below has the sponsor’s details.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: SYHX1901

Start the discussion